[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9e9Vo6xy-N3p_HpGU-athkj9W-t_Xyp0Cxxa7htLgzA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"European Institute of Oncology",[4],171,false,75,15,83442,12,131,[14,17,20,22,24,27,29,32],{"name":15,"count":16},"Breast Cancer",39,{"name":18,"count":19},"Lung Cancer",6,{"name":21,"count":19},"Colorectal Cancer",{"name":23,"count":19},"Head and Neck Cancer",{"name":25,"count":26},"Prostate Cancer",5,{"name":28,"count":26},"Metastatic Breast Cancer",{"name":30,"count":31},"Neuroendocrine Tumors",4,{"name":33,"count":31},"Cancer",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03971045","Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer","2024-12-01","Pembrolizumab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05554003","Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study","2024-12-31","Temozolomide",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06727357","Next Generation Sequencing-based \"Oncochip\" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP","2025-03","Chemotherapy",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06033092","Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion","2025-12","Tamoxifen 10 mg",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06972693","NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma","2025-12-30","BRCA testing",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06690840","Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","2026-12-15","Atezolizumab in combination with Cyclophosphamide and Vinorelbine",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06611514","Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer","2027-01-01","Prasterone",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07066969","Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer","2027-04","Sophia DDM",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06723990","Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX","2027-11","Neoadjuvant standard treatment for HER2+",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT07395336","Elacestrant and Exemestane for Patients With Pretreated HR+\u002FHER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)","2028-12","elacestrant and exemestane",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,119,140,174,207,228,250,280,300,322,340,366,387,424,470,502,524,551,569,587,605,623,649,673,696,722,740,764,786,821,839,857,884,902,925,948,973,991,1014,1040,1066,1090,1116,1140,1164,1196,1214,1232,1250,1268],{"intervention":59,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":117},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":58},[107],{"nctId":56,"briefTitle":57,"status":108,"phases":109,"primaryCompletion":58,"completion":58,"start":110,"enrollment":111,"conditions":112,"interventions":116},"ACTIVE_NOT_RECRUITING",[90],"2018-06-12",323,[113,114,115],"Ovarian Carcinoma","Fallopian Tube Carcinoma","Primary Peritoneal Carcinoma",[59],{"trials":118,"activeCount":98},[],{"intervention":69,"totalTrials":94,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":136,"NA":138},{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":94,"soonestReadout":68},[129],{"nctId":66,"briefTitle":67,"status":130,"phases":131,"primaryCompletion":68,"completion":68,"start":38,"enrollment":132,"conditions":133,"interventions":135},"NOT_YET_RECRUITING",[89],95,[134],"Women With Breast Cancer",[69],{"trials":137,"activeCount":98},[],{"trials":139,"activeCount":98},[],{"intervention":141,"totalTrials":142,"cells":143},"chemotherapy",2,{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":157,"PHASE4":170,"NA":172},{"trials":145,"activeCount":98},[],{"trials":147,"activeCount":98},[],{"trials":149,"activeCount":94,"soonestReadout":48},[150],{"nctId":46,"briefTitle":47,"status":108,"phases":151,"primaryCompletion":48,"completion":48,"start":152,"enrollment":153,"conditions":154,"interventions":156},[88],"2019-09-26",38,[155],"Breast Cancer, Metastatic Breast Cancer",[49],{"trials":158,"activeCount":98},[159],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT00002896","Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer","UNKNOWN",[89],"1993-09",774,[21],[141,168,169],"fluorouracil","leucovorin calcium",{"trials":171,"activeCount":98},[],{"trials":173,"activeCount":98},[],{"intervention":39,"totalTrials":142,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":177,"activeCount":98},[],{"trials":179,"activeCount":98},[],{"trials":181,"activeCount":94,"soonestReadout":38},[182,192],{"nctId":183,"briefTitle":184,"status":185,"phases":186,"primaryCompletion":187,"completion":187,"start":188,"enrollment":98,"conditions":189,"interventions":191},"NCT03448666","ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases","WITHDRAWN",[88],"2023-12-01","2021-03-01",[190],"Malignant Melanoma",[39],{"nctId":36,"briefTitle":37,"status":193,"phases":194,"primaryCompletion":38,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"RECRUITING",[88],"2025-03-01","2020-05-20",46,[15,199],"Chest Wall Tumor",[39],{"trials":202,"activeCount":98},[],{"trials":204,"activeCount":98},[],{"trials":206,"activeCount":98},[],{"intervention":44,"totalTrials":94,"cells":208},{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":210,"activeCount":98},[],{"trials":212,"activeCount":98},[],{"trials":214,"activeCount":94,"soonestReadout":43},[215],{"nctId":41,"briefTitle":42,"status":193,"phases":216,"primaryCompletion":43,"completion":43,"start":217,"enrollment":197,"conditions":218,"interventions":221},[88],"2022-01-14",[30,219,220],"Frailty","Chemotherapy Effect",[44],{"trials":223,"activeCount":98},[],{"trials":225,"activeCount":98},[],{"trials":227,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":231,"activeCount":98},[],{"trials":233,"activeCount":98},[],{"trials":235,"activeCount":94,"soonestReadout":63},[236],{"nctId":61,"briefTitle":62,"status":193,"phases":237,"primaryCompletion":63,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},[88],"2027-02-15","2025-03-06",45,[242],"Triple Negative Breast Cancer",[64],{"trials":245,"activeCount":98},[],{"trials":247,"activeCount":98},[],{"trials":249,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":253,"activeCount":98},[],{"trials":255,"activeCount":98},[],{"trials":257,"activeCount":94,"soonestReadout":53},[258],{"nctId":51,"briefTitle":52,"status":108,"phases":259,"primaryCompletion":53,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":273},[88],"2026-01","2024-06-21",200,[264,265,266,267,268,269,270,271,272],"BRCA Mutation","PALB2 Gene Mutation","Ductal Carcinoma in Situ","Lobular Carcinoma in Situ","ATM Gene Mutation","CHEK2 Gene Mutation","CDH1 Gene Mutation","RAD51C Gene Mutation","RAD51D Gene Mutation",[54],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"intervention":84,"totalTrials":94,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":98},[],{"trials":287,"activeCount":94,"soonestReadout":83},[288],{"nctId":81,"briefTitle":82,"status":193,"phases":289,"primaryCompletion":83,"completion":83,"start":290,"enrollment":291,"conditions":292,"interventions":293},[88],"2026-05-11",26,[15],[84],{"trials":295,"activeCount":98},[],{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":303,"activeCount":98},[],{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"trials":313,"activeCount":94,"soonestReadout":78},[314],{"nctId":76,"briefTitle":77,"status":193,"phases":315,"primaryCompletion":78,"completion":78,"start":316,"enrollment":317,"conditions":318,"interventions":320},[],"2024-10-24",60,[319],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[79,321],"Adjuvant standard treatment for HER2+",{"intervention":321,"totalTrials":94,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":325,"activeCount":98},[],{"trials":327,"activeCount":98},[],{"trials":329,"activeCount":98},[],{"trials":331,"activeCount":98},[],{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":94,"soonestReadout":78},[336],{"nctId":76,"briefTitle":77,"status":193,"phases":337,"primaryCompletion":78,"completion":78,"start":316,"enrollment":317,"conditions":338,"interventions":339},[],[319],[79,321],{"intervention":341,"totalTrials":94,"cells":342},"ctDNA detection",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":98},[],{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":98},[],{"trials":354,"activeCount":94,"soonestReadout":359},[355],{"nctId":356,"briefTitle":357,"status":130,"phases":358,"primaryCompletion":359,"completion":359,"start":53,"enrollment":360,"conditions":361,"interventions":365},"NCT07268469","Minimal Residual Disease in Solid Malignancies",[91],"2033-07",840,[15,362,25,363,364],"Non Small Cell Lung Cancer","High Grade Serous Ovarian Cancer","Gastric Cancer",[341],{"intervention":74,"totalTrials":94,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":376,"NA":378},{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":98},[],{"trials":375,"activeCount":98},[],{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":94,"soonestReadout":73},[380],{"nctId":71,"briefTitle":72,"status":130,"phases":381,"primaryCompletion":73,"completion":73,"start":382,"enrollment":383,"conditions":384,"interventions":386},[91],"2026-01-22",20,[385],"Endometrial Cancer",[74],{"intervention":388,"totalTrials":142,"cells":389},"Enalapril",{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":408,"NA":422},{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":98},[398],{"nctId":399,"briefTitle":400,"status":162,"phases":401,"primaryCompletion":402,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":407},"NCT01968200","Prevention of Anthracycline-induced Cardiotoxicity",[89],"2019-12","2023-12","2012-12",268,[33],[388],{"trials":409,"activeCount":98},[410],{"nctId":411,"briefTitle":412,"status":413,"phases":414,"primaryCompletion":415,"completion":415,"start":416,"enrollment":417,"conditions":418,"interventions":421},"NCT00292526","Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients","COMPLETED",[90],"2011-11","2000-11",114,[419,420],"Cardiotoxicity","Chemotherapeutic Toxicity",[388],{"trials":423,"activeCount":98},[],{"intervention":168,"totalTrials":31,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":466,"NA":468},{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":98},[],{"trials":431,"activeCount":98},[],{"trials":433,"activeCount":98},[434,444,448,459],{"nctId":435,"briefTitle":436,"status":162,"phases":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT00003063","Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer",[89],"1991-11",1050,[21],[442,168,169,443],"recombinant interferon alfa","levamisole hydrochloride",{"nctId":160,"briefTitle":161,"status":162,"phases":445,"start":164,"enrollment":165,"conditions":446,"interventions":447},[89],[21],[141,168,169],{"nctId":449,"briefTitle":450,"status":413,"phases":451,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":457},"NCT00002897","Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus",[89],"2001-06","1992-07",240,[456],"Esophageal Cancer",[458,168],"cisplatin",{"nctId":460,"briefTitle":461,"status":162,"phases":462,"start":463,"enrollment":454,"conditions":464,"interventions":465},"NCT00002747","Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer",[89],"1992-09",[23],[458,168],{"trials":467,"activeCount":98},[],{"trials":469,"activeCount":98},[],{"intervention":458,"totalTrials":471,"cells":472},3,{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":498,"NA":500},{"trials":474,"activeCount":98},[],{"trials":476,"activeCount":98},[],{"trials":478,"activeCount":98},[],{"trials":480,"activeCount":98},[481,490,494],{"nctId":482,"briefTitle":483,"status":162,"phases":484,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT00003053","Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed",[89],"1994-01",750,[18],[458,489],"etoposide",{"nctId":449,"briefTitle":450,"status":413,"phases":491,"completion":452,"start":453,"enrollment":454,"conditions":492,"interventions":493},[89],[456],[458,168],{"nctId":460,"briefTitle":461,"status":162,"phases":495,"start":463,"enrollment":454,"conditions":496,"interventions":497},[89],[23],[458,168],{"trials":499,"activeCount":98},[],{"trials":501,"activeCount":98},[],{"intervention":169,"totalTrials":142,"cells":503},{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":520,"NA":522},{"trials":505,"activeCount":98},[],{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[512,516],{"nctId":435,"briefTitle":436,"status":162,"phases":513,"start":438,"enrollment":439,"conditions":514,"interventions":515},[89],[21],[442,168,169,443],{"nctId":160,"briefTitle":161,"status":162,"phases":517,"start":164,"enrollment":165,"conditions":518,"interventions":519},[89],[21],[141,168,169],{"trials":521,"activeCount":98},[],{"trials":523,"activeCount":98},[],{"intervention":525,"totalTrials":94,"cells":526},"Metoprolol",{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":547,"NA":549},{"trials":528,"activeCount":98},[],{"trials":530,"activeCount":98},[],{"trials":532,"activeCount":98},[],{"trials":534,"activeCount":98},[535],{"nctId":536,"briefTitle":537,"status":413,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT01281787","PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer",[89],"2013-06","2013-10","2008-04",320,[18,544],"Atrial Fibrillation",[525,546],"Losartan",{"trials":548,"activeCount":98},[],{"trials":550,"activeCount":98},[],{"intervention":546,"totalTrials":94,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":559,"PHASE4":565,"NA":567},{"trials":554,"activeCount":98},[],{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":98},[561],{"nctId":536,"briefTitle":537,"status":413,"phases":562,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":563,"interventions":564},[89],[18,544],[525,546],{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":98},[],{"intervention":442,"totalTrials":94,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":583,"NA":585},{"trials":572,"activeCount":98},[],{"trials":574,"activeCount":98},[],{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[579],{"nctId":435,"briefTitle":436,"status":162,"phases":580,"start":438,"enrollment":439,"conditions":581,"interventions":582},[89],[21],[442,168,169,443],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"intervention":443,"totalTrials":94,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":601,"NA":603},{"trials":590,"activeCount":98},[],{"trials":592,"activeCount":98},[],{"trials":594,"activeCount":98},[],{"trials":596,"activeCount":98},[597],{"nctId":435,"briefTitle":436,"status":162,"phases":598,"start":438,"enrollment":439,"conditions":599,"interventions":600},[89],[21],[442,168,169,443],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"intervention":489,"totalTrials":94,"cells":606},{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":619,"NA":621},{"trials":608,"activeCount":98},[],{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":98},[],{"trials":614,"activeCount":98},[615],{"nctId":482,"briefTitle":483,"status":162,"phases":616,"start":485,"enrollment":486,"conditions":617,"interventions":618},[89],[18],[458,489],{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"intervention":624,"totalTrials":94,"cells":625},"Vitamin D3",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":645,"NA":647},{"trials":627,"activeCount":98},[],{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":98},[],{"trials":633,"activeCount":98},[634],{"nctId":635,"briefTitle":636,"status":637,"phases":638,"primaryCompletion":639,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT01264874","MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients","TERMINATED",[89],"2017-07","2010-05",150,[643],"Melanoma",[624],{"trials":646,"activeCount":98},[],{"trials":648,"activeCount":98},[],{"intervention":650,"totalTrials":94,"cells":651},"Tamoxifen",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":669,"NA":671},{"trials":653,"activeCount":98},[],{"trials":655,"activeCount":98},[],{"trials":657,"activeCount":98},[],{"trials":659,"activeCount":98},[660],{"nctId":661,"briefTitle":662,"status":162,"phases":663,"primaryCompletion":664,"completion":403,"start":665,"enrollment":666,"conditions":667,"interventions":668},"NCT01579734","Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) Users",[89],"2018-12","2002-03",1884,[15],[650],{"trials":670,"activeCount":98},[],{"trials":672,"activeCount":98},[],{"intervention":674,"totalTrials":94,"cells":675},"tamoxifen citrate",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":692,"NA":694},{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[684],{"nctId":685,"briefTitle":686,"status":413,"phases":687,"completion":404,"start":688,"enrollment":689,"conditions":690,"interventions":691},"NCT00002720","Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer",[89],"1995-12",642,[15],[674],{"trials":693,"activeCount":98},[],{"trials":695,"activeCount":98},[],{"intervention":697,"totalTrials":94,"cells":698},"Bisacodyl plus PEG-CS",{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":718,"NA":720},{"trials":700,"activeCount":98},[],{"trials":702,"activeCount":98},[],{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[707],{"nctId":708,"briefTitle":709,"status":413,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":714,"interventions":716},"NCT01685853","Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One",[89],"2012-03","2011-04",164,[715],"Colonoscopy",[697,717],"PEG 4 litres split",{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[],{"intervention":717,"totalTrials":94,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":736,"NA":738},{"trials":725,"activeCount":98},[],{"trials":727,"activeCount":98},[],{"trials":729,"activeCount":98},[],{"trials":731,"activeCount":98},[732],{"nctId":708,"briefTitle":709,"status":413,"phases":733,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":734,"interventions":735},[89],[715],[697,717],{"trials":737,"activeCount":98},[],{"trials":739,"activeCount":98},[],{"intervention":741,"totalTrials":94,"cells":742},"Fenretinide",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":760,"NA":762},{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":98},[],{"trials":748,"activeCount":98},[],{"trials":750,"activeCount":98},[751],{"nctId":752,"briefTitle":753,"status":637,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":383,"conditions":757,"interventions":759},"NCT01479192","Fenretinide in Healthy Young Women at Genetic and Familial Risk",[89],"2015-12","2009-12",[758],"High-Risk Cancer",[741],{"trials":761,"activeCount":98},[],{"trials":763,"activeCount":98},[],{"intervention":765,"totalTrials":94,"cells":766},"aldesleukin",{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":782,"NA":784},{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":98},[775],{"nctId":776,"briefTitle":777,"status":162,"phases":778,"start":463,"enrollment":779,"conditions":780,"interventions":781},"NCT00002702","Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx",[89],260,[23],[765],{"trials":783,"activeCount":98},[],{"trials":785,"activeCount":98},[],{"intervention":787,"totalTrials":142,"cells":788},"Cyclophosphamide",{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"trials":794,"activeCount":98},[795,807],{"nctId":796,"briefTitle":797,"status":162,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":804},"NCT04304352","Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients",[88],"2023-12-31","2011-07-29",162,[803],"Advanced Breast Cancer",[805,806,787],"Vinorelbine","Capecitabine",{"nctId":808,"briefTitle":809,"status":162,"phases":810,"primaryCompletion":403,"completion":403,"start":811,"enrollment":383,"conditions":812,"interventions":814},"NCT01374841","Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors",[88],"2010-08",[813],"Hematologic Neoplasms",[787],{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[],{"intervention":805,"totalTrials":94,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":833,"PHASE4":835,"NA":837},{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[829],{"nctId":796,"briefTitle":797,"status":162,"phases":830,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":831,"interventions":832},[88],[803],[805,806,787],{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":98},[],{"trials":838,"activeCount":98},[],{"intervention":806,"totalTrials":94,"cells":840},{"EARLY_PHASE1":841,"PHASE1":843,"PHASE2":845,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":842,"activeCount":98},[],{"trials":844,"activeCount":98},[],{"trials":846,"activeCount":98},[847],{"nctId":796,"briefTitle":797,"status":162,"phases":848,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":849,"interventions":850},[88],[803],[805,806,787],{"trials":852,"activeCount":98},[],{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"intervention":858,"totalTrials":94,"cells":859},"Rituximab",{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":878,"PHASE4":880,"NA":882},{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"trials":865,"activeCount":98},[866],{"nctId":867,"briefTitle":868,"status":637,"phases":869,"primaryCompletion":870,"completion":870,"start":871,"enrollment":872,"conditions":873,"interventions":876},"NCT01446900","R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma",[88],"2017-12","2011-01",25,[874,875],"Chronic Lymphocytic Leukaemia","Small Lymphocytic Lymphoma",[858,877],"Cladribine",{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[],{"trials":883,"activeCount":98},[],{"intervention":877,"totalTrials":94,"cells":885},{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[],{"trials":891,"activeCount":98},[892],{"nctId":867,"briefTitle":868,"status":637,"phases":893,"primaryCompletion":870,"completion":870,"start":871,"enrollment":872,"conditions":894,"interventions":895},[88],[874,875],[858,877],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[],{"intervention":903,"totalTrials":94,"cells":904},"Caelyx®",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":919,"PHASE4":921,"NA":923},{"trials":906,"activeCount":98},[],{"trials":908,"activeCount":98},[],{"trials":910,"activeCount":98},[911],{"nctId":912,"briefTitle":913,"status":162,"phases":914,"primaryCompletion":799,"completion":799,"start":915,"enrollment":916,"conditions":917,"interventions":918},"NCT03712956","CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER",[88],"2016-03-25",63,[15],[903],{"trials":920,"activeCount":98},[],{"trials":922,"activeCount":98},[],{"trials":924,"activeCount":98},[],{"intervention":926,"totalTrials":94,"cells":927},"Ipilimumab",{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":929,"activeCount":98},[],{"trials":931,"activeCount":98},[],{"trials":933,"activeCount":98},[934],{"nctId":935,"briefTitle":936,"status":162,"phases":937,"primaryCompletion":43,"completion":43,"start":938,"enrollment":939,"conditions":940,"interventions":941},"NCT06566391","Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma",[88],"2019-03-05",35,[643],[926],{"trials":943,"activeCount":98},[],{"trials":945,"activeCount":98},[],{"trials":947,"activeCount":98},[],{"intervention":949,"totalTrials":94,"cells":950},"nimesulide",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[957],{"nctId":958,"briefTitle":959,"status":413,"phases":960,"primaryCompletion":961,"completion":962,"start":963,"enrollment":641,"conditions":964,"interventions":965},"NCT01500577","A Prevention Trial in Subjects at High Risk for Breast Cancer",[88],"2012-11","2013-07","2005-04",[15],[949,966],"Simvastatin",{"trials":968,"activeCount":98},[],{"trials":970,"activeCount":98},[],{"trials":972,"activeCount":98},[],{"intervention":966,"totalTrials":94,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":985,"PHASE4":987,"NA":989},{"trials":976,"activeCount":98},[],{"trials":978,"activeCount":98},[],{"trials":980,"activeCount":98},[981],{"nctId":958,"briefTitle":959,"status":413,"phases":982,"primaryCompletion":961,"completion":962,"start":963,"enrollment":641,"conditions":983,"interventions":984},[88],[15],[949,966],{"trials":986,"activeCount":98},[],{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":98},[],{"intervention":992,"totalTrials":94,"cells":993},"Anti-Thymocyte Globulin",{"EARLY_PHASE1":994,"PHASE1":996,"PHASE2":998,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":995,"activeCount":98},[],{"trials":997,"activeCount":98},[],{"trials":999,"activeCount":98},[1000],{"nctId":1001,"briefTitle":1002,"status":637,"phases":1003,"primaryCompletion":962,"completion":1004,"start":1005,"enrollment":471,"conditions":1006,"interventions":1007},"NCT01375023","Allogenic Haematopoietic Cell Transplantation for Patients With Refractory \"Triple Negative\" Breast Cancer",[88],"2013-12","2009-06",[15],[992],{"trials":1009,"activeCount":98},[],{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[],{"intervention":1015,"totalTrials":94,"cells":1016},"perioperative chemotherapy",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[1023],{"nctId":1024,"briefTitle":1025,"status":413,"phases":1026,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1033},"NCT00301548","Perioperative Chemotherapy After Primary Chemotherapy for Locally Advanced Breast Cancer",[88],"2005-06","2000-02",172,[1031,1032],"Breast Neoplasms","Carcinoma",[1015],{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":98},[],{"intervention":1041,"totalTrials":94,"cells":1042},"peptide receptor radionuclide therapy with Y-90-DOTATOC",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1060,"PHASE4":1062,"NA":1064},{"trials":1044,"activeCount":98},[],{"trials":1046,"activeCount":98},[],{"trials":1048,"activeCount":98},[1049],{"nctId":1050,"briefTitle":1051,"status":637,"phases":1052,"primaryCompletion":1053,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1059},"NCT05568017","Neoadjuvant PRRT With Y-90-DOTATOC in pNET",[88],"2022-09-23","2024-11-11","2020-09-15",11,[1058],"Pancreatic Neuroendocrine Tumor",[1041],{"trials":1061,"activeCount":98},[],{"trials":1063,"activeCount":98},[],{"trials":1065,"activeCount":98},[],{"intervention":1067,"totalTrials":94,"cells":1068},"Androgen deprivation therapy",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1070,"activeCount":98},[],{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[1075],{"nctId":1076,"briefTitle":1077,"status":162,"phases":1078,"primaryCompletion":187,"completion":1079,"start":1080,"enrollment":641,"conditions":1081,"interventions":1083},"NCT03940235","Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis",[88],"2024-04-01","2019-10-01",[1082],"Oligometastatic Prostate Cancer",[1067],{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":98},[],{"intervention":1091,"totalTrials":94,"cells":1092},"Everolimus 10 mg daily",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1110,"PHASE4":1112,"NA":1114},{"trials":1094,"activeCount":98},[],{"trials":1096,"activeCount":98},[],{"trials":1098,"activeCount":98},[1099],{"nctId":1100,"briefTitle":1101,"status":413,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT02305810","A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus",[88],"2017-01-12","2018-06","2013-09",54,[1108],"Pancreatic Neuroendocrine Tumour Metastatic",[1091],{"trials":1111,"activeCount":98},[],{"trials":1113,"activeCount":98},[],{"trials":1115,"activeCount":98},[],{"intervention":1117,"totalTrials":94,"cells":1118},"Y90-DOTA-Tyr3-Octreotide",{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[1125],{"nctId":1126,"briefTitle":1127,"status":413,"phases":1128,"primaryCompletion":1129,"completion":1130,"start":1131,"enrollment":26,"conditions":1132,"interventions":1133},"NCT04296149","Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe",[88],"2018-12-31","2019-12-31","2017-02-16",[30],[1117],{"trials":1135,"activeCount":98},[],{"trials":1137,"activeCount":98},[],{"trials":1139,"activeCount":98},[],{"intervention":1141,"totalTrials":94,"cells":1142},"Cetuximab plus Radiotherapy",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1158,"PHASE4":1160,"NA":1162},{"trials":1144,"activeCount":98},[],{"trials":1146,"activeCount":98},[],{"trials":1148,"activeCount":98},[1149],{"nctId":1150,"briefTitle":1151,"status":162,"phases":1152,"primaryCompletion":664,"completion":403,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1157},"NCT03001570","Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District",[88],"2014-01",10,[1156],"Carcinoma of the Head and Neck",[1141],{"trials":1159,"activeCount":98},[],{"trials":1161,"activeCount":98},[],{"trials":1163,"activeCount":98},[],{"intervention":1165,"totalTrials":94,"cells":1166},"Cohort A: primarily operable disease, candidate to adjuvant",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[],{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[1179],{"nctId":1180,"briefTitle":1181,"status":162,"phases":1182,"primaryCompletion":43,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1190},"NCT06321640","Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.",[],"2025-12-31","2022-07-08",265,[15,18,643,23,1187,21,1188,1189],"Urothelial Carcinoma","Liver Metastases","Lung Metastases",[1165,1191,1192,1193,1194,1195],"Cohort B: locally advanced disease","Cohort C: metastatic disease","Cohort D: Progressive disease","Cohort E: Hematological neoplasms","Cohort F: Toxicity",{"intervention":1191,"totalTrials":94,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1199,"activeCount":98},[],{"trials":1201,"activeCount":98},[],{"trials":1203,"activeCount":98},[],{"trials":1205,"activeCount":98},[],{"trials":1207,"activeCount":98},[],{"trials":1209,"activeCount":98},[1210],{"nctId":1180,"briefTitle":1181,"status":162,"phases":1211,"primaryCompletion":43,"completion":1183,"start":1184,"enrollment":1185,"conditions":1212,"interventions":1213},[],[15,18,643,23,1187,21,1188,1189],[1165,1191,1192,1193,1194,1195],{"intervention":1192,"totalTrials":94,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":98},[],{"trials":1223,"activeCount":98},[],{"trials":1225,"activeCount":98},[],{"trials":1227,"activeCount":98},[1228],{"nctId":1180,"briefTitle":1181,"status":162,"phases":1229,"primaryCompletion":43,"completion":1183,"start":1184,"enrollment":1185,"conditions":1230,"interventions":1231},[],[15,18,643,23,1187,21,1188,1189],[1165,1191,1192,1193,1194,1195],{"intervention":1193,"totalTrials":94,"cells":1233},{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1242,"NA":1244},{"trials":1235,"activeCount":98},[],{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[1246],{"nctId":1180,"briefTitle":1181,"status":162,"phases":1247,"primaryCompletion":43,"completion":1183,"start":1184,"enrollment":1185,"conditions":1248,"interventions":1249},[],[15,18,643,23,1187,21,1188,1189],[1165,1191,1192,1193,1194,1195],{"intervention":1194,"totalTrials":94,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1253,"activeCount":98},[],{"trials":1255,"activeCount":98},[],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[],{"trials":1261,"activeCount":98},[],{"trials":1263,"activeCount":98},[1264],{"nctId":1180,"briefTitle":1181,"status":162,"phases":1265,"primaryCompletion":43,"completion":1183,"start":1184,"enrollment":1185,"conditions":1266,"interventions":1267},[],[15,18,643,23,1187,21,1188,1189],[1165,1191,1192,1193,1194,1195],{"intervention":1195,"totalTrials":94,"cells":1269},{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[1282],{"nctId":1180,"briefTitle":1181,"status":162,"phases":1283,"primaryCompletion":43,"completion":1183,"start":1184,"enrollment":1185,"conditions":1284,"interventions":1285},[],[15,18,643,23,1187,21,1188,1189],[1165,1191,1192,1193,1194,1195]]